Dr. Ahn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2013 - 2017
Methodist Hospital (Houston)Residency, Internal Medicine, 2010 - 2013
Catholic University Medical CollegeClass of 2008, M.D.
Certifications & Licensure
MA State Medical License 2021 - 2026
NH State Medical License 2023 - 2025
MD State Medical License 2017 - 2022
DC State Medical License 2013 - 2017- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.Matthew S Davids, Christine E Ryan, Benjamin L Lampson, Yue Ren, Svitlana Tyekucheva
Journal of Clinical Oncology. 2024-12-07 - Consensus Recommendations from the 2024 Lymphoma Research Foundation Workshop on Treatment Selection and Sequencing in CLL or SLL.Jacob D Soumerai, Jacqueline Claudia Barrientos, Inhye E Ahn, Catherine C Coombs, Douglas E Gladstone
Blood Advances. 2024-11-19 - Masked Arginine Vasopressin Deficiency in a Kidney Transplant Recipient With Posttransplant Lymphoproliferative Disorder.Annie Liu, Lakshmi Nayak, Waihay J Wong, Inhye E Ahn, Naoka Murakami
Kidney International Reports. 2024-09-01
Abstracts/Posters
- A CD19/CD3 Bispecific Antibody Induces Superior T Cell Responses Against Chronic Lymphocytic Leukemia When Combined with IbrutinibInhye E Ahn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Show Expansion of T-Cell Clonotypes Composed of Antitumor Cytotoxic CD8+ T-CellsInhye E Ahn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Whole Exome Sequencing Reveals Multiple Driver Events in Chronic Lymphocytic Leukemia Patients with Acquired Ibrutinib ResistanceInhye E Ahn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
Clinically Indicated Ibrutinib Interruptions Do Not Limit Long-Term Benefit in CLLJune 27th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
